Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Taysha Gene Therapies Inc shares valued at $942,000 were sold by Nagendran Sukumar on Jan 12 ’26. At $4.71 per share, Nagendran Sukumar sold 200,000 shares. The insider’s holdings dropped to 1,006,439 shares worth approximately $5.07 million following the completion of this transaction.
Also, Nagendran Sukumar purchased 200,000 shares, netting a total of over 996,000 in proceeds.
Before that, Nagendran Sukumar had sold 260,047 shares from its account. In a trade valued at $1,172,812, the President and Head of R&D traded Taysha Gene Therapies Inc shares for $4.51 each. Upon closing the transaction, the insider’s holdings decreased to 260,047 shares, worth approximately $5.07 million.
As published in their initiating research note from Raymond James on October 21, 2025, Taysha Gene Therapies Inc [TSHA] has been a Strong buy and the price target has been revised to $13. Analysts at BofA Securities started covering the stock with ‘”a Buy”‘ outlook in a report released in mid July. As of June 27, 2024, BMO Capital Markets has initiated its “an Outperform” rating for TSHA. Earlier on April 09, 2024, Piper Sandler initiated its rating. Their recommendation was “an Overweight” for TSHA stock.
Analyzing TSHA Stock Performance
On last trading session, Taysha Gene Therapies Inc [NASDAQ: TSHA] rose 2.86% to $5.04. The stock’s lowest price that day was $4.845, but it reached a high of $5.17 in the same session. During the last five days, there has been a drop of approximately -5.08%. Over the course of the year, Taysha Gene Therapies Inc shares have jumped approximately 201.80%.
Is Taysha Gene Therapies Inc subject to short interest?
Stocks of Taysha Gene Therapies Inc saw a sharp rise in short interest on 2025-12-31 jumping by 7.0 million shares to 56.03 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 49.04 million shares. A jump of 12.49% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 16.16 of the overall float, the days-to-cover ratio (short ratio) jumped to 16.16.
Which companies own the most shares of Taysha Gene Therapies Inc (TSHA)?
In terms of Taysha Gene Therapies Inc share price expectations, FactSet research, analysts set an average price target of 11 in the next 12 months, up nearly 124.49% from the previous closing price of $4.9. Analysts anticipate Taysha Gene Therapies Inc stock to reach 13 by 2026, with the lowest price target being 8. In spite of this, 8 analysts ranked Taysha Gene Therapies Inc stock as Buy at the end of 2026. On February 01, 2023, Jefferies assigned a price target of “a Hold” to the stock and downgraded coverage with a $1.50.
